Please assess the completion status of the following clinical trial:

Trial Title: A Study of ICP-022 in the Treatment of Recurrent or Refractory Waldenstrom Macroglobulinemia

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Key Inclusion criteria:~1. Clinical and histologically confirmed giant globulinemia Fahrenheit (WM Ii International Working Group Standards, IWWM-2, 2003) (Owen et al., 2003)~2. At least one treatment indication is met (7th WM International Working Group standards, IWWM-7) (Dimopoulos et al., 2014)~3. With the lowest serum IgM value \>2 times ULN as the efficacy evaluation index~4. ECOG physical strength score 0-2~5. Voluntary written informed consent prior to trial screening.~Key Exclusion Criteria:~1. Present or prior history of other malignant neoplasms, unless radical treatment has been performed and there is no evidence of recurrence or metastasis in the last 5 years~2. Amyloidosis and central nervous system (CNS) involvement caused by WM~3. Demonstrate disease transformation~4. Patients who had received autologous stem cell transplantation within the previous 6 months~5. A history of organ transplantation or allogeneic bone marrow transplantation~NOTE: Other protocol defined Inclusion/Exclusion criteria may apply.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- ICP-022 (Type: EXPERIMENTAL): Subjects will take ICP-022 150mg once daily (QD).

Based on this trial design, predict the completion outcome and termination type (if applicable).